Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

描述(由申请人提供)：加州大学戴维斯分校(UC Davis)的临床肿瘤学研究职业发展计划(CDP)将培训初级教师学者成为独立的、以患者为中心的癌症研究人员。这些学者将进行转化性研究，以开发实验室驱动的临床试验，旨在根据单个患者肿瘤或肿瘤类型的潜在分子特征优化新的治疗方法。CDP将培养出来自不同背景的新教职员工，他们是团队科学领域的熟练领导者。加州大学戴维斯分校在培养下一代临床医生科学家方面处于有利地位，这是因为其出色的患者护理；在临床-翻译研究(包括癌症临床试验)方面长期存在且资金充足的基础设施，包括我们的NCI指定的癌症中心和NCRR资助的临床和翻译科学中心(CTSC)；实验室-临床相关科学方面的经验；以及建立的机构间和机构内联合体，以及其他资源。在成功完成三年工资支持的核心课程后，学者将获得加州大学戴维斯癌症中心临床癌症研究证书。我们将结合关键的教学、研究和职业发展部分，在一个为期三年的计划中培养独立和富有成效的临床肿瘤学研究人员。我们将通过以下具体目标来实现我们的目标：1)提供有指导的、基于能力的教学课程，以便学者可以整合基础、翻译和临床科学知识，以发现和/或评估更有效的癌症治疗方法，从而改善患者的预后；2)监督根据每位CDP学者的兴趣和需求定制的以患者为中心的个性化研究项目(由研究人员发起的临床试验)；以及3)监督CDP学者的培训，以确保逐步开发出高质量的“最终产品”：一位完全胜任的、以跨学科为导向的临床科学家，他能够成功地使用新型研究试剂或设备进行癌症转化性临床试验。CDP的课程将以基础/翻译和临床科学的两个研究轨道为指导。每个受训者都将按照两名独立资助的资深教员(一名基础/翻译导师和一名临床导师)的计划，获得适当的、综合的教学和实践指导的研究培训，以便能够成功地解决其中一条途径的研究问题。我们将独特的团队科学和跨学科研究培训场所纳入课程，以利用加州大学戴维斯分校其他培训项目的优势，特别是那些位于CTSC的培训项目。我们的总体目标是开发成功的、独立的临床癌症研究人员，他们将能够根据他们对癌症生物学背后的复杂机制以及他们如何在个体患者和广大人群中表现出疾病的理解，合作开发和测试新的癌症治疗方法。因此，我们需要让临床医生精通实验室科学家的语言，反之亦然。我们的多学科方法在理解和开发针对肿瘤疾病的有针对性的治疗方法方面的长期成功，关键取决于新一代多学科研究人员的培训，他们拥有远远超出其最初学科边界的想法和技能。

DESCRIPTION (provided by applicant): The Clinical Oncology Research Career Development Program (CDP) at the University of California, Davis (UC Davis) will train junior faculty scholars to be independent, patient-oriented cancer researchers. The scholars will conduct translational research to develop laboratory-driven clinical trials designed to optimize novel therapeutic approaches based on the underlying molecular profiles of individual patient tumors or tumor types. The CDP will produce new faculty members from diverse backgrounds who are skilled leaders in team science. UC Davis is well-positioned to train the next generation of clinician scientists in oncology because of its outstanding patient care; long-standing and well-funded infrastructure in clinical-translational investigation (including cancer clinical trials), including our NCI-designated Cancer Center and NCRR-funded Clinical and Translational Science Center (CTSC); experience in laboratory-clinical correlative science; and established inter- and intra-institution consortia, among other resources. Upon successful completion of a three-year, salary-supported core curriculum, Scholars will receive a UC Davis Cancer Center Certificate in Clinical Cancer Research. We will combine key didactic, research, and career development components to produce independent and productive clinical oncology researchers over the course of a three-year program. We will accomplish our goals through the following specific aims: 1) 1) Offer a mentored, competency-based didactic curriculum so Scholars can integrate basic, translational, and clinical science knowledge to discover and/or evaluate more effective treatments for cancer that improve patient outcome; 2) Oversee individualized patient oriented research projects (investigator-initiated clinical trials) customized to the interests and needs of each CDP Scholar; and 3) Provide oversight of CDP Scholar training to ensure the progressive development of a high-quality "end-product": a fully competent interdisciplinary-oriented clinician scientist who can successfully conduct translational cancer clinical trials with investigational new agents or devices. The curriculum for the CDP will be guided by two research tracks in Basic/Translational and Clinical science. Each trainee will gain appropriate, integrated didactic and "hands-on" mentored research training following a plan supervised by two senior, independently funded faculty members (one Basic/Translational mentor and one Clinical mentor) to be able to successfully tackle research questions in one of these tracks. We have incorporated unique venues for training in team science and interdisciplinary research into the curriculum in order to take advantage of the strengths of other training programs at UC Davis, particularly those housed in the CTSC. Our overall goal is to develop successful, independent clinical cancer researchers who will be able to work in teams to develop and test new cancer treatments based upon their understanding of the complex mechanisms underlying cancer biology and how they manifest disease in individual patients as well as in broad populations. Thus, we need to make the clinician well-versed in the language of the laboratory scientist and vice-versa. The long-term success of our multidisciplinary approach to understanding and developing targeted treatments for oncologic disease critically depends upon the training of a new generation of multidisciplinary researchers who possess ideas and skills that go far beyond their initial disciplinary boundaries.